These outcomes corroborate the data obtained from confocal imaging, confirming that HER2-scFv-modified macrophage membrane camouflage NPs acquire specific tumor-targeting and biomimetic properties, which are critical for efficient drug delivery to HER2+ tumor cells. Here, ERBB2 is linked to neoplasm.